We are live on
!
Find out more
NMC
NEA Management Company Portfolio holdings
AUM
$1.76B
1-Year Est. Return
223.33%
This Fund
S&P 500
This Quarter
Est. Return
-13.42%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.51B
AUM Growth
-$65.2M
(-4.1%)
Cap. Flow
+$241M
Cap. Flow
% of AUM
16.02%
Top 10 Holdings %
Top 10 Hldgs %
78.74%
Holding
39
New
5
Increased
3
Reduced
1
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADAP
Adaptimmune Therapeutics
ADAP
|
+$80.8M |
| 2 |
Senseonics Holdings Inc
SENS
|
+$74M |
| 3 |
TSRO
TESARO, Inc.
TSRO
|
+$57M |
| 4 |
KA
Kineta, Inc. Common Stock
KA
|
+$24.4M |
| 5 |
ELGX
Endologix Inc
ELGX
|
+$20.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TRIV
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
|
+$26.2M |
| 2 |
NVRO
NEVRO CORP.
NVRO
|
+$19.6M |
| 3 |
AKTX
Akari Therapeutics
AKTX
|
+$1.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.03% |
| 2 | Communication Services | 11.7% |
| 3 | Technology | 6.13% |
| 4 | Consumer Discretionary | 1.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Champions Oncology
CSBR
$74.5M
| $5.69M | 0.38% |
1,562,500
| – | – |
|
|
ORKA
27
Oruka Therapeutics
ORKA
$5.82B
| $5.07M | 0.34% |
6,760
| – | – |
|
|
ZSAN
28
DELISTED
Zosano Pharma Corporation
ZSAN
| $4.96M | 0.33% |
3,084
| – | – |
|
|
VIRX
29
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $4.21M | 0.28% |
37,094
| – | – |
|
|
ARQL
30
DELISTED
Arqule Inc
ARQL
| $4.03M | 0.27% |
2,520,316
| – | – |
|
|
ROKA
31
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
| $2.22M | 0.15% |
322,043
| – | – |
|
32
Avalo Therapeutics
AVTX
$965M
| $2.22M | 0.15% |
207
| – | – |
|
|
OREX
33
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $2.08M | 0.14% |
370,900
| – | – |
|
|
PRTK
34
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $1.9M | 0.13% |
125,004
| – | – |
|
35
Gyre Therapeutics
GYRE
$641M
| $1.1M | 0.07% |
5,799
| – | – |
|
|
AGRX
36
DELISTED
Agile Therapeutics
AGRX
| $829K | 0.06% |
67
| – | – |
|
|
AKTX
37
Akari Therapeutics
AKTX
$13.8M
| – | – |
-152
| Closed | -$1.77M |
|
|
TRIV
38
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
| – | – |
-3,945,191
| Closed | -$26.2M |
|
Similar funds
NM
SLF
CCIA
SW
CGH
PWP
CIP
GD
NEA Management Company's Q1 2016 Portfolio in Review
As of Q1 2016, NEA Management Company held 39 positions worth $1.51B, down 4.1% from $1.57B the previous quarter. Its ten largest holdings account for 79% of the portfolio.
NEA Management Company deployed $241M of net new capital in Q1 2016, opening 5 new positions and adding to 3 existing holdings. Its largest new stake was Adaptimmune Therapeutics: 9,880,999 shares worth $80.3M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 72% a quarter earlier, followed by Communication Services and Technology.
On the sell side, the largest reduction was NEVRO CORP., an estimated $19.6M trimmed.
- NEA Management Company's largest Q1 2016 buy was Adaptimmune Therapeutics: 9,880,999 shares worth $80.3M.
- NEA Management Company added most to TESARO, Inc. in Q1 2016, an estimated $57M increase.
- NEA Management Company's biggest Q1 2016 reduction was NEVRO CORP., cutting an estimated $19.6M.
- NEA Management Company fully exited TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK in Q1 2016, selling an estimated $26.2M.
- NEA Management Company's ten largest holdings make up 79% of its $1.51B portfolio in Q1 2016.
- NEA Management Company opened 5 new positions and closed 2 in Q1 2016.
- NEA Management Company's portfolio value fell 4.1% quarter-over-quarter to $1.51B.
Based on NEA Management Company's 13F filing for Q1 2016, filed 11 May 2016.